As shown in Fig. 7a–c, when using a suboptimal dosage of celecoxib that did not lead to tumor size reduction in control mice (vehicle vs celecoxib in scrambled KOs, black and gray lines, respectively), we found that deletion of MFGE8, KLK5, and KLK7 all resulted in a significant restoration of the celecoxib effect and markedly decreased tumor size by 31.3%, 18.6%, and 20.7%, respectively, following celecoxib treatment compared to the vehicle-treated mice (Fig. 7a–c, colored lanes). The gene discussed is KLK5; the disease is neoplasm.